NorthWest Biotherapeutics Inc (NWBO)

[notbrad]

And what you are leaving out is that the total enrollment for both of DNDN's 2 trials was less than 348. And the length of time in development is fairly similar with both companies. With regards to manufacturing, I would rather that it is outsourced at this stage of development so that NWBO shareholders are not on the hook for plant and equipment. It's a sensible decision even it means paying a bit extra for services.

NWBO just needs enough manufacturing capacity to begin commercialization. Then we gradually scale up capacity to meet demand. It would be stupid to set up manufacturing to meet peak demand when it's still not approved. By the way, Dendreon's 3 plants cost about $150M. You take that out of the equation and it's still a huge difference.